Recent data suggest that signal transduction may have a critical role in the development and regulation of the metastatic phenotype. Here, we investigated the role of c-Src activation in the process of human colon cancer metastasis to the liver. Our data, derived from two dierent sets of human colon cancer cell line metastatic variants, suggest that not only do highly-metastatic cells display constitutively elevated c-Src protein kinase activity when compared to poorly metastatic cells, but also that receptor tyrosine kinases participate in the ligand-activation of c-Src above basal levels. Speci®cally, the epidermal growth factor receptor (EGFR), p185HER2/Neu and the hepatocyte growth factor receptor (c-Met) appear to be linked to the process because they preferentially activate c-Src in highlymetastatic cells. EGFR was found to associate with c-Src in colon cancer cells and speci®c inhibitors of the EGFR resulted in a reduction of c-Src activity to basal levels. In addition, c-Src transfectants displayed partially-activated EGFRs, suggesting a feedback role for c-Src in the regulation of the EGFR. p185HER2/Neu was also identi®ed in immunocomplexes of c-Src following ligand activation of the EGFR, but only in highly-metastatic cells. Collectively, these observations suggest a paradigm whereby c-Src interacts with multiple cell-surface growth factors in a catalytic fashion for the development of tumor cells with metastatic potential.
Introduction
Colon cancer is a common disease which leads to death in nearly 50% of cases often through one ®nal common pathway ± liver metastasis. The cellular mechanisms that govern the process of human colon cancer metastasis to the liver appear to be complex. While the over-expression of numerous proteins belonging to dierent structural and functional classes (adhesion molecules, angiogenesis factors, growth factors, invasive enzymes) have been implicated in a multi-step, non-random process, the mechanisms responsible for producing the metastatic phenotype remain poorly understood (Yeatman and Nicolson, 1993) .
Candidates for molecules that might orchestrate the complex process underlying the metastatic phenotype through signal transduction and selective gene expression include the oncogenes that encode protein tyrosine kinases. Earlier studies have ®rmly established a role for both receptor (Baserga, 1994; Bottaro et al., 1991; D'Ambrosio et al., 1995; Khazaie et al., 1993) and non-receptor family tyrosine kinases (Egan et al., 1987a,b; Greenberg et al., 1989) in the transformation of normal cells. In particular, the product of the human src proto-oncogene, c-Src, has been implicated in the progression of colon cancer (Garcia et al., 1991; Cartwright et al., 1989 Cartwright et al., , 1990 Talamonti et al., 1991; Termuhlen et al., 1993) . Studies utilizing fresh human tissue specimens have demonstrated a strong association between c-Src protein kinase activity with advancing tumor stage. There is a strong positive correlation between c-Src activity and tumor progression from non-malignant polyps to invasive cancers to metastatic foci. In particular, c-Src activation appears to be stronger for metastases, with increases averaging 90-fold over levels detected in normal mucosa (Talamonti et al., 1991) . While not all advanced tumors produce elevated levels of c-Src activity, most do, and these are generally moderately or well dierentiated tumors. Poorly dierentiated tumors appear to display signi®cantly reduced c-Src activity, suggesting a role for c-Src in dierentiation (Weber et al., 1992) . Similar results have been noted for breast cancers Muller, 1994, 1995a; Ottenho-Kal et al., 1992) . Other studies have also found elevations of kinase activity for additional Srcfamily members, such as Yes (Pena et al., 1995) and Lck (Mayer and Ballhausen, 1996) , in colon and associated epithelial cancers. Consistent with these clinical data are experiments that clearly show that v-Src, the product of the Rous sarcoma virus, is fully capable of transforming normal ®broblasts (Antczak and Kung, 1990; Jove and Hanafusa, 1987) . v-Src transformation results in increases in the in vitro and in vivo invasiveness, cell motility, soft agar growth, and tumorigenicity. Signi®cantly, the metastatic phenotype reliably has been produced by v-Src transfection of normal cells, a phenotype that appears to be more potent than that produced by activated Ras (Egan et al., 1987; Tatsuka et al., 1996) .
Despite clinical and experimental observations suggesting a central role for c-Src in tumor induction and progression, experiments involving transfection of normal human c-Src into non-malignant ®broblasts, surprisingly, are not very eective in producing transformation (Maa et al., 1995) . Only when mutationally-active c-Src or its counterpart, v-Src, are transfected, does malignant transformation reliably occur (Egan et al., 1987a,b; Bjorge et al., 1995) . This transformation is presumably related to the loss of the C-terminal, negative regulatory, tyrosine phosphorylation site or to changes in the kinase domain itself, which result in the constitutive activation of the kinase domain (Cooper and Howell, 1993) . To date, however, mutations in human c-Src (Wang et al., 1991) have not been identi®ed in human colon cancer. Thus, it is apparent that, with the exception of poorly-differentiated tumors, highly activated c-Src may be frequently important for the production of human colon cancer cells capable of distant metastasis. Collectively, these observations have led us to examine mechanisms other than mutation by which c-Src can become activated in metastatic human colon cancer.
Based on the recent ®nding that the co-transfection of EGFR and c-Src produces remarkable levels of transformation of normal ®broblasts (Maa et al., 1995) compared to EGFR or c-Src alone, we have hypothesized that c-Src, in cooperation with receptor tyrosine kinases, might play an important, catalytic role in the development of the human colon cancer metastatic phenotype. In this report, we have studied the role of c-Src and its molecular interactions with receptor tyrosine kinases using two dierent sets of human colon cancer liver-metastatic variants. We have demonstrated signi®cant increases in c-Src activity associated with highly-metastatic cells that are not found in poorly-metastatic cells, and we have found this activity to be regulated by EGFR, p185HER2/ Neu, and c-Met. We propose that this interaction with receptor tyrosine kinases may be one mechanism by which c-Src may become activated in cells with high metastatic potential and that this activation may be linked to the development of the metastatic phenotype.
Results

c-Src protein levels and activity in fresh human tissue specimens
Human tissue samples were derived from normal colonic mucosa, non-malignant polyps, invasive colon cancers, and liver-metastatic, colon cancer foci. Samples were subjected to Western blot analysis of cSrc levels ( Figure 1a ) and to c-Src kinase assays (Figure 1b) . Results of previous studies were con®rmed in that an association between increasing c-Src protein level and tumor progression and stage was noted, as well as a trend for increasing c-Src autokinase activity.
Constitutive c-Src protein kinase activity is elevated in highly metastatic human colon cancer cell lines Two dierent sets of poorly and highly metastatic colon cancer cell lines (derived from two geneticallyunrelated patients) were analysed for c-Src protein levels by Western blot and for activity by c-Src kinase assays (Figure 2a Similar results were found using a completely dierent set of poorly-metastatic (SW480) and highly-metastatic (SW620) cell lines (Figure 2d ). Dierences in kinase activity were maintained despite various culture conditions (1 vs 10% serum) and were not explained on the basis of c-Src mutation or on the basis of c-Src kinase (CSK) protein levels. Sequencing of the entire cSrc cDNA coding sequence produced no mismatches when compared with national human database sequences (data not shown) and Western blot analysis of CSK levels showed no dierences between poorly and highly metastatic cells (data not shown).
Ligand activation of receptor kinases enhances c-Src activity in highly metastatic cell lines Again, two dierent sets of human colon cancer metastatic variant cell lines were treated with 100 ng/ ml epidermal growth factor (EGF) for 10 min prior to analysis (Figure 2a and d,`+EGF' panels). In both cases, EGF treatment reproducibly augmented c-Src activity in highly-metastatic cell lines (KM12 SM, KM12 L4A, and SW 620) but not in poorly metastatic cell lines (KM12 C, SW 480). Densitometry analysis suggested that enolase activation was increased nearly twofold ( Figure 2b ) and autokinase activity was increased by nearly ®vefold (Figure 2c ) over untreated controls. Recombinant hepatocyte growth factor also appeared to activate c-Src via the c-Met receptor in metastatic cells (KM12 SM, KM12 L4A) more so than non-metastatic cells (KM12 C) (Figure 3 ). This activation was con®rmed by c-Src kinase assays (panel 1) as well as by anti-phosphotyrosine Western blots of c-Src immunoprecipitates (panel 2).
Constitutive receptor tyrosine kinase levels and activity in highly metastatic cell lines
To explore the hypothesis that constitutive Src activity might be related to the protein levels of receptor family tyrosine kinases and to their activity, both the epidermal growth factor receptor and the hepatocyte growth factor receptor were analysed for protein levels 
Ligand activation of the EGFR causes a weak association with c-Src
Using a 1% CHAPS lysis buer, we were able to identify an association between the EGFR and c-Src in colon cancer cell lines ( Figure 6 ). Wild type cell lines (C, SM, L4A) as well as a cell line transfected with normal human c-Src (Src-4) were all tested for this association. While a weak association between Src and EGFR was detected in untreated cells, EGF treatment appeared to increase the association in the metastatic cell lines (SM, L4A) and in cell line transfectants stably over-expressing c-Src (Src-4). We attempted to demonstrate this association in fresh human tumor specimens but were unsuccessful (data not shown).
Speci®c inhibitors of EGFR block ligand activation of EGF and associated c-Src activation
To further understand the relationship between the EGFR and c-Src, the KM12 cell lines were pre-treated with a drug that speci®cally blocks EGFR activation (PD 158780) (Rewcastle et al., 1996) and then treated with 100 ng/ml EGF for 10 min prior to analysis of whole cell lysates by phosphotyrosine Western blots (Figure 7 ). EGF stimulation of untreated cells predictably enhanced autophosphorylation of protein bands consistent with EGFR (170 kDa) and c-Src (60 kDa) in the highly-metastatic cell lines (KM12 SM, KM12 L4A) but had no apparent eect on c-Src in the poorly-metastatic cell line (KM12 C), mirroring previous experiments (see Figure 2a) . Interestingly, EGF stimulation reproducibly decreased the phosphorylation of a protein of approximately 70 kDa in all three cell lines. The eect of PD 158780 at two dierent doses was to reduce the amount of c-Src phosphorylation to its constitutive baseline level or below in both of the highly metastatic cell lines (KM12 SM, KM12 L4A), with little or no apparent eect on the poorly-metastatic cell line (KM12 C).
p185HER2/Neu oncogene product co-precipitates with Src in highly-metastatic cells
Because of the potential for regulation of c-Src by other receptors, we tested for the presence of other oncoproteins that might be linked to the process of cSrc activation. The p185HER2/Neu oncoprotein was initially selected as it has been reported to be associated with the EGFR and c-Src in breast cancer cell lines (Luttrell et al., 1994; Muthuswamy and Muller, 1995b; . p185HER2/Neu was detected in all three KM12 cell lines but levels were signi®cantly higher in both of the highly-metastatic cell lines (KM12 SM, KM12 L4A) (Figure 8a ). We were able to co-precipitate the p185HER2/Neu oncoprotein with c-Src in the highly- (Figure 8b ). The p185HER2/Neu protein that co-precipitated with c-Src was detected in untreated KM12 L4A cells but not in KM12 SM and KM12 C cells; however, following EGF ligand stimulation, p185HER2/Neu was detected in precipitates with c-Src in both of the highly metastatic cell lines (KM12 L4A4KM12 SM). Thus, just as EGF ligand binding to the EGFR induces EGFR and c-Src association, it also induces Neu association in highly-metastatic cells.
c-Src overexpression induces phosphorylation of multiple protein substrates
Compared to a control cell line shown not to produce detectable c-Src message or protein, the Src-4 clone was found to possess constitutive phosphorylation of at least three prominent bands (170 kDa, 120 kDa, and 85 kDa) ( Figure 9 ). The 170 kDa phosphoprotein in unstimulated cells co-migrates with the prominent 170 kDa phosphoprotein in the EGF stimulated cells, suggesting its identity to be the EGFR. The identity of the other substrates has yet to be determined.
Discussion
Our ®ndings suggest that both c-Src and multiple receptor family tyrosine kinases may be linked to development of the colon cancer metastatic phenotype. These data are consistent with observations using human tissues that levels of c-Src kinase activity are frequently increased in tumors with greater metastatic potential and that regulation of this activity may be critical to the growth and progression of colon cancer cells (Cartwright et al., 1989 (Cartwright et al., , 1990 Talamonti et al., 1991; Termuhlen et al., 1993; Garcia et al., 1991) . We have studied two separate sets of human colon cancer cell line metastatic variants and have observed in both that highly metastatic cells display greater levels of constitutive c-Src activity and are more responsive to ligand activation by receptor family kinases than are poorly-metastatic cells. Our data corroborate the ®ndings of others that suggest that c-Src probably does not act alone (Luttrell et al., 1994; Maa et al., 1995; Muthuswamy and Muller, 1995b) . The evidence supporting a cooperative role between c-Src and the receptor family kinases in the promotion of metastatic behaviour is increasing. First, the activation of human c-Src does not appear to be related to mutational events. We and others (Wang et al., 1991) have screened multiple human colon cancer cell lines for mutations in c-Src and have found none (W Mao, R Irby, TJ Yeatman, unpublished data). Apparently, the mutations responsible for the activation of v-Src and other related forms of mutationally activated c-Src have not been observed in human tissues. In addition, we found no signi®cant dierences in CSK levels between poorly and highly-metastatic cells. Yet, despite observing only slight increases in cSrc protein levels in advanced human malignancies and in highly-metastatic cell lines, c-Src kinase levels are signi®cantly increased.
While mechanisms (Cooper and Howell, 1993 ) other than mutational activation of c-Src have not yet been excluded, such as those implicating speci®c phosphatases acting on the C-terminus of c-Src, data exists supporting the interaction of c-Src with membrane-associated receptor kinases. Candidate receptor family tyrosine kinases include EGFR, cMet and p185HER2/Neu. We selected the EGFR as the principal target for study because data from other epithelial cancers, such as breast cancer, suggest that the EGFR may directly interact with c-Src (Luttrell et al., 1994) . In addition, EGFR has been shown to play a signi®cant role in the promotion of tumor growth and progression (Chakrabarty et al., 1995; Khazaie et al., 1993; Radinsky, 1993; Radinsky et al., 1995) . Our data showed that c-Src is preferentially activated by ligand binding of the EGFR and that c-Src associates with the EGFR, particularly after ligand stimulation in the highly-metastatic cells or in transfected cells overexpressing c-Src. This is the ®rst report of this observation, which suggests an association between human c-Src and EGFR in metastatic human colon cancer. These ®ndings support those of Luttrell et al. (1994) , who were the ®rst to identify this association in breast cancer. In addition, our data using c-Src stable transfectants suggest that c-Src apparently phosphorylates a 170 kDa protein that co-migrates with the EGFR, again suggesting a relationship between c-Src and EGFR, potentially through the SH2 domain of c-Src. A 120 kDa protein as well as a 85 kDa protein, whose identities have yet to be determined, are also phosphorylated in c-Src transfectants. A recent report by Brunton et al. (1997) corroborates our ®ndings in that they demonstrated an EGF induced increase in c-Src kinase activity in an in vitro, chemically-induced model of colon cancer. Data derived from experiments using v-Src and other mutationally-active forms of c-Src have also provided strong evidence for a role for c-Src and receptor kinases in metastasis. v-Src has been very useful in the identi®cation of potential c-Src functions as well as substrates, v-Src is known to phosphorylate tyrosine residues of many dierent cellular proteins (Brown and Cooper, 1996) . Among these substrates are proteins reported to be associated with the metastatic process, such as cytoskeletal proteins (annexin II), celladhesion molecules (b1 integrin, b-catenin, p120 CAS , FAK), and ras-dependent pathways. c-Src has also been reported to upregulate the expression of genes encoding invasive enzymes of the metalloproteinase class (Hamaguchi et al., 1995) that may be critical to the metastatic phenotype. While no mutationally activated forms of c-Src have been described in colon cancer, these data suggest a role for activated c-Src in the process of tumor progression.
The association between Src and the plasma membrane has also been shown to be critical for Src function and lends support to the hypothesis that human c-Src is activated by membrane kinases (Weernink and Rijksen, 1995) . It has been reported that v-Src is transforming in NIH3T3 ®broblasts, but when the myristoyl group is removed, it can no longer associate with the cellular plasma membrane and consequently, loses its transforming activity (Kamps et al., 1986) . In addition, it has also been demonstrated that mutations removing the myristoyl group from human c-Src eliminate a hyper-mitogenic response induced by EGF (Wilson et al., 1989) . These data, coupled with the knowledge that natural mutations in human c-Src have not been identi®ed, support the concept that c-Src protein kinase activation by membrane associated proteins is critical. We suggest that receptor tyrosine kinases are good candidates for active participants in this transforming process, the most important of which appears to be the EGFR. It has been reported, however, that EGFR over-expression in breast cancer cells at levels 60-fold greater than mock controls results in only a twofold increase in c-Src activation (Weernink et al., 1994) . Others have shown a correlation between the level of EGFR expression and the degree of Src-family kinase activation, but only after a speci®c level of EGFR has been expressed (Osherov and Levitzki, 1994) . These observations point to the possibility that other components in addition to the EGFR may be limiting in c-Src activation. Our data have also suggested that at least two additional growth factor receptors, p185HER2/Neu, and c-Met, may have a role in the activation of c-Src in human colon cancer cells. In breast cancer cells, p185HER2/Neu was recently to participate in the activation of c-Src by EGFR described (Luttrell et al., 1994) . We found this to be the case in the KM12 SM and KM12 L4A cell lines with known high metastatic potential. Similarly, our ®nding that ligand activation of c-Met by hepatocyte growth factor induces activation of c-Src con®rms one other report (Ponzetto et al., 1994) of this relationship in gastric cancer cells. In addition, c-Met has been suggested to play a role in the progression of colon cancer (Di Renzo et al., 1995) .
Collectively, these data provide evidence for a paradigm in colon cancer progression that implicates multiple receptor tyrosine kinases in the control and catalytic activation of c-Src, which may be critical to the development of the metastatic phenotype. Unanswered questions include the exact relationship between c-Src, receptor family kinases, and downstream targets of c-Src. And, while our data suggest that c-Src is downstream of the EGFR, they also suggest that it may feedback to the EGFR. Further investigation will be required to identify the substrates of c-Src that are linked to the metastatic process, and how their regulation through signal transduction leads to selective gene expression favoring cancer cells with the ability to spread and survive in distant organ environments.
Materials and methods
Cell lines and growth conditions
Two sets of well-described human colon cancer cell line metastatic variants were selected for this study. The KM12 cell lines (KM12 C, KM12 SM, KM12 L4A) were kindly provided by I Fidler. KM12 C, the parental, poorlymetastatic cell line, was derived from a Dukes' B human colon cancer (Morikawa et al., 1988) . From it were derived KM12 SM and KM12 L4A, two dierent highly-metastatic cell lines. KM12 SM was the product of a spontaneous liver metastasis following the injection of KM12 C intracecally into the nude mouse. KM12 L4A was derived, as well, from KM12 C, but via a completely dierent mechanism. KM12 L4A was derived following the intrasplenic injection of KM12 C in the nude mouse. It represents the fourth passage of the KM12 C cell line through the spleen and liver. Both KM12 SM and KM12 L4A are reproducibly highly-metastatic to the liver in the nude mouse intrasplenic injection assay. The metastatic behavior of these cell lines has been previously described (Jessup et al., 1989 (Jessup et al., , 1988 Morikawa et al., 1988a,b; Yeatman et al., 1996) .
The SW 480, SW 620 and Di® were a gift from Gary E Gallick, MD Anderson (Houston, TX). The SW 480 and SW 620 human colon cancer cell lines have also been well-studied (Coey et al., 1987) and their behavior in the nude mouse intrasplenic injection assay is predictable (Shah et al., 1994; Witty et al., 1994; Zirvi et al., 1993) . The SW 480 cell line was derived from a primary Dukes' C colon cancer and the SW 620 cell line was derived from a lymph node metastasis in the same patient. While the SW 480 cell line is poorlymetastatic to the liver in the nude mouse, the SW 620 cell line is highly-metastatic.
All cell lines were grown as monolayers in plastic Petri dishes (Falcon, Lincoln Park, PA) with standard culture medium (RPMI-1640) supplemented with 10% fetal bovine serum (FBS) (GIBCO, Grand Island, NY). All cells were cultured at 378C in a 5% humidi®ed CO 2 incubator. At 75 ± 80% con¯uency, tumor cell monolayers were harvested within 4 min into medium with 10% FBS using a solution of trypsin (0.05%)/EDTA (53 mM) (GIBCO, Grand Island, NY).
Human tissues
All human tissues were obtained from the H Lee Mott Cancer Center human tissue bank. All tissues were orphan pathological specimens collected under an approved IRB protocol within 5 min of surgical resection and then snap frozen in liquid nitrogen.
Antibodies, growth factors, and conditions for treatment Anti-EGF Receptor antibody (Ab), Anti-c-Met Ab, Antip185HER2/Neu Ab and antiphosphotyrosine Ab PY20 were all purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-Src antibody MAB 327 was a gift from JS Brugge (Ariad Pharmaceuticals) and Ab N-17 was obtained from NCI Repository. Anti-Src (pp60 src ) GD11 monoclonal Ab was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY) for use in Western blots. Sheep anti-mouse Ig and goat anti-rabbit Ig were from Amersham Life Science. All cells were serum starved overnight and then treated with growth factors for 10 min at 378C prior to lysis and further analysis. Growth factor concentrations: EGF (GIBCO, Grand Island, NY) 100 ng/ml; HGF (Collaborative Research) 200 ng/ml. The EGF receptor inhibitor PD158780 was used to pretreat cells for 2 h prior to growth factor stimulation in doses ranging from 0 ± 1000 nM.
Western blotting and immunoprecipitation
Following treatment of cell cultures with growth factors, cells were lysed in ice-cold RIPA buer (10 mM Tris pH 7.4, 150 mM NaCl, 10% glycerol, 5 mM EDTA, 1% Triton X-100, 0.5% deoxycholate, 1 mM PMSF, 1 mM Na orthovanadate, 10 mg/ml leupeptin, 10 mg/ml apoprotinin). Lysates were incubated with either 5 mg anti-Src AB (MAB 327) or 2 mg anti-EGFR AB for 1 h at 48C on a rotator, then with 40 ml protein A-agarose (GIBCO, Grand Island, NY) overnight at 48C. After immunoprecipitation with the indicated antibody and separation by SDS-polyacrylamide gel electrophoresis, the proteins were transfered to nitrocellulose. The nitrocellulose blots were blocked in Tris-buered saline with 0.1% Tween 20 containing chicken serum ovalbumin (4%) for 4 h and incubated for 18 h at 48C with the following primary antibodies: (1) anti-EGFR Ab 2 mg/ml; (2) anti-c-Met Ab 2 mg/ml; (3) antiNeu Ab 2 mg/ml; (4) anti-pTyr Ab 2 mg/ml. At the end of the incubation period, the ®lters were washed and incubated with the appropriate horseradish peroxidaseconjugated secondary antibodies for 1 h at room temperature, the ®lters were then washed and exposed with the enhanced chemiluminescence detection system (Amersham). For experiments designed to detect an association between EGFR and Src, 1% CHAPS (3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate) (Sigma Chemical Co., St Louis, MO) buer was used to replace the detergents in the RIPA buer.
Src kinase assay
Cell lysates were clari®ed by centrifugation for 15 min at 48C and then immunoprecipitated with anti-Src Ab (MAB 327) and washed three times with RIPA buer and three times in Tris buer (40 mM Tris pH 7.4). The samples were resuspended in 30 ml of kinase reaction buer (20 mM Tris pH 7.4, 5 mM magnesium chloride, 100 mM Na orthovanadate) containing 20 mCi [ 32 P]ATP/reaction and aciddenatured enolase (1 mg/reaction) (Sigma Chemical Co., St Louis, MO) as exogenous substrate. The samples were incubated for 15 min at room temperature, resuspended in electrophoresis sample buer and boiled for 5 min. The sample was centrifuged at 16 000 g brie¯y and the supernatant was loaded onto a SDS-10% polyacrylamide gel and then electrophoresed and autoradiographed.
Construction of human c-Src expression plasmids
Wild-type cDNA for human c-Src containing the fulllength coding sequence was kindly provided by D Fujita (University of Calgary, Canada) in a Bluescript KS plasmid (Bjorge et al., 1995) . The c-Src insert was released from the Bluescript KS plasmid using the HindIII and NcoI restriction enzymes (GIBCO, Grand Island, NY) and cloned into the HindIII/XbaI sites in the pcDNA 3.1 (+) expression plasmid (Invitrogen, San Diego, CA). The resulting expression plasmid containing the c-Src fragment was con®rmed by sequencing the PCR fragment and junctional regions.
Transfection and selection of stably transfected cell lines
A helium driven gene gun (Agracetus, Inc, Middleton, WI) was used for DNA transfections using methodologies previously described (Mahvi et al., 1996) . The c-Src expression vector was used to transfect the poorlymetastatic KM12 C cell line. Twenty-four hours following transfection, cells were incubated in complete medium with 800 mg/ml G418 antibiotic (GIBCO, Grand Island, NY). After a period of approximately three weeks, multiple colonies of G418-resistant cells appeared and were harvested individually. Colonies were then expanded and tested by Western blot analysis for c-Src expression. One of these transfected, G418-resistant colonies was con®rmed to produce no detectable c-Src message in Northern analysis and was used as the`control' cell line for another (Src-4) colony found to overexpress c-Src protein and message nearly 10-fold over the wild-type KM12 C cell line and the control clone.
